Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftriaxone + sulbactam is a combination antibiotic used to treat a wide range of bacterial infections caused by susceptible organisms. Ceftriaxone is a third-generation cephalosporin antibiotic that works by inhibiting the synthesis of the bacterial cell wall through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Sulbactam is a beta-lactamase inhibitor that prevents bacterial enzymes from breaking down ceftriaxone, thereby enhancing its effectiveness against beta-lactamase-producing bacteria. This combination is particularly effective against multidrug-resistant bacteria and is commonly used for conditions such as meningitis, pneumonia (community- and hospital-acquired), otitis media, intra-abdominal infections, complicated urinary tract infections, and other serious bacterial infections[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftriaxone + sulbactam.